Last Week in Biomedicine | May 18–22 | Part 2 of 2: Bladder Cancer Conjugate, HPV Cervical Win

Part 2 of our May 18–22, 2026 roundup digs into a first-in-class Bicycle Toxin Conjugate for bladder cancer, a non-surgical DNA immunotherapy clearing HPV-driven cervical pre-cancer, anoff-the-shelf cancer vaccine extending remission in ovarian cancer, an engineered IL-2 antibody pulling responses out of melanoma that had resisted every checkpoint inhibitor, and a topical hair-loss drug that may finally give men a side-effect-light alternative to finasteride.
In Part 2 we cover:6. Bicycle Therapeutics — Zelenectide Pevedotin (BT8009) for Advanced Bladder (Urothelial) Cancer (Phase 2/3)7. ApolloBio (with INOVIO) — VGX-3100 for HPV-16/18 High-Grade Cervical Pre-Cancer (Phase 3)8. OSE Immunotherapeutics — Tedopi for Platinum-Sensitive Recurrent Ovarian Cancer (Phase 2)9. Aulos Bioscience — Imneskibart (AU-007) for Checkpoint-Inhibitor-Refractory Metastatic Melanoma (Phase 2)10. Cosmo Pharmaceuticals — Clascoterone 5% Topical Solution for Male Androgenetic Alopecia (Phase 3)
The Bicycle Therapeutics readout is a fascinating proof-of-concept. Instead of a giant antibody hauling chemo to a tumor, Bicycle uses a tiny constrained peptide as the targeting head — small enough to penetrate solid tumors more deeply and clear from the body faster than a traditional antibody-drugconjugate. Positive Phase 2 data in advanced bladder cancer suggest this 'bicycle' platform could become a new way to deliver targeted chemotherapy across many cancers. We also pull back to identify the big pipeline themes connecting all ten of this week's readouts.
Catch Part 1 if you missed it. Subscribe at TrialBreaks.com
#biomedicine #clinicaltrials #science #oncology #bladdercancer #ovariancancer #melanoma #immunotherapy #HPV #cervicalcancer #dermatology #hairloss #vaccines#drugdiscovery #ADC

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(17)

Last Week in Biomedicine | Jun 29–Jul 3 | Part 2 of 2: Baby Pompe Disease Trial, DLBCL Combo Win

Part 2 covers three more standout stories from the same week: a Phase 3 trial that gives babies with a devastating enzyme disease a fighting chance, a first-of-its-kind cell therapy approved to make b...

9 Heinä 36min

Last Week in Biomedicine | Jun 29–Jul 3 | Part 1 of 2: CRISPR for Toddlers, KRAS Lung Cancer Win

CRISPR gene editing crossed a major line this week: the FDA now allows Casgevy — the first CRISPR therapy of any kind — for children as young as 2 with sickle cell disease, meaning we can potentially ...

7 Heinä 43min

Last Week in Biomedicine | June 22–26 | Part 2 of 2: Thyroid Eye Disease, ADHD + Anxiety, Skyrizi Kids

Part 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a top-selling psoriasis b...

2 Heinä 41min

Last Week in Biomedicine | June 22–26 | Part 1 of 2: LSD Depression Phase 3, Trodelvy TNBC Approval

This week, an LSD-based therapy hit its main goal in a Phase 3 depression trial — and two huge breast cancer approvals landed at the FDA on the same week. In Part 1 we cover:1. Definium Therapeutics —...

30 Kesä 36min

Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hyper...

25 Kesä 25min

Last Week in Biomedicine | June 14–20 | Part 1 of 2: CRISPR HAE Cure, Narcolepsy Orexin Breakthrough

This week opened with one of the most significant gene-editing milestones in clinical medicine: a single CRISPR infusion cut hereditary angioedema attacks by 87 percent in a Phase 3 trial, published t...

23 Kesä 34min

Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary

Part 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in psoriasis, and Agios's...

18 Kesä 21min

Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill

A blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill cleared two Phase 3 trials. ...

16 Kesä 20min